BergenstalRM, Hachmann-NielsenE, KvistK, et al.Increased derived time in range is associated with reduced risk of major adverse cardiovascular events, severe hypoglycemia, and microvascular events in type 2 diabetes: A post hoc analysis of devote. Diabetes Technol Ther, 2023; 25(6):378–383.
2.
BeckRW. The association of time in range and diabetic complications: The evidence is strong. Diabetes Technol Ther, 2023; 25(6):375–377.
3.
BattelinoT, DanneT, BergenstalRM, et al.Clinical targets for continuous glucose monitoring data interpretation: Recommendations from the international consensus on time in range. Diabetes Care, 2019; 42(8):1593–1603.
4.
BergenstalRM, AhmannAJ, BaileyT, et al.Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: The ambulatory glucose profile (AGP). Diabetes Technol Ther, 2013; 15(3):198–211.
5.
ShahVN, DuBoseSN, LiZ, et al.Continuous glucose monitoring profiles in healthy non-diabetic participants: A multicenter prospective study. J Clin Endocrinol Metab, 2019; 104(10):4356–4364.
6.
PassanisiS, PionaC, SalzanoG, et al.Aiming for the best glycemic control beyond time in range: Time in tight range as a new continuous glucose monitoring metric in children and adolescents with type 1 diabetes using different treatment modalities. Diabetes Technol Ther, 2024; 26(3):161–166.
7.
AkturkHK, BattelinoT, CastanedaJ, et al.Future of time-in-range goals in the era of advanced hybrid closed-loop automated insulin delivery systems. Diabetes Technol Ther, 2024; 26(S3):S102–S106.
8.
BeckRW, RaghinaruD, CalhounP, BergenstalRM. A comparison of continuous glucose monitoring-measured time-in-range 70–180 mg/dL versus time-in-tight-range 70–140 mg/dL. Diabetes Technol Ther, 2024; 26(3):151–155.
9.
BergenstalRM, BeckRW, CloseKL, et al.Glucose management indicator (GMI): A new term for estimating A1C from continuous glucose monitoring. Diabetes Care, 2018; 41:2275–2280.
10.
DunnTC, AjjanRA, BergenstalRM, XuY. Is it time to move beyond TIR to TITR? Real-world data from over 20,000 users of continuous glucose monitoring in patients with type 1 and type 2 diabetes. Diabetes Technol Ther, 2024; 26(3):203–210.
11.
The Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes, 1995; 44:968–983.
12.
LachinJM, GenuthS, NathanDM, et al.; for the DCCT/EDIC Research Group. Effect of glycemic exposure on the risk of microvascular complications in the Diabetes Control and Complications Trial-revisited. Diabetes, 2008; 57:995–1001.
13.
LindM, PivodicA, SvenssonA-M, et al.HbA1c level as a risk factor for retinopathy and nephropathy in children and adults with type 1 diabetes: Swedish population based cohort study. BMJ, 2019; 366:I4894.
14.
LindM, SvenssonA-M, KosiborodM, et al.Glycemic control and excess mortality in type 1 diabetes. N Eng J Med, 2014; 371:1972–1982.
15.
BattelinoT, AlexanderCM, AmielSA, et al.Continuous glucose monitoring and metrics for clinical trials: An International Consensus Statement. Lancet Diabetes Endocrinol, 2023; 11(1):42–57.
